FDA Policy for REMS Reqmts during COVID-19

Health Care, Pharma Industry, Strategic Planning

FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.

Read the Policy now

 

 

Related Education Resources.

All Resources

Covid-19 Supply Chain: Managing Risk & Disruption

Topics: Conference, COVID-19, Supply Chain

Executive Summary

Members

EAP 103: Expanded Access Module 3 Supply Planning

Topics: Additional Concepts, Closeout, EAP, Execution, Forecasting / Planning

Presentation

Members

The Bioethics Associated with Expanded Access/Early Access to Investigational Products Outside of Clinical Trials

Topic: EAP

White Paper

Free

Become a member

Global Clinical Supplies Group

Join GCSG for full access...

to our educational resources, conference materials and our directory of more than 480 Clinical Supply colleagues. Experience the culture of collaboration, It only takes approximately 3 minutes 22 seconds.

Please note that membership is included and FREE of charge when you sign up for an event.

Join Renew